Akari Therapeutics (AKTX) Net Equity Issued and Repurchased (2012 - 2025)

Akari Therapeutics (AKTX) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $479560.0 in Q4 2025.

• For the quarter ending Q4 2025, Net Equity Issued and Repurchased fell 84.67% year-over-year to $479560.0; the trailing twelve-month figure through Dec 2025 stood at $6.4 million (down 46.18% YoY), and the FY2025 full-year result was $10.7 million, down 9.23% from the prior year.
• Net Equity Issued and Repurchased eased to $479560.0 in Q4 2025, from $4.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $7.1 million in Q2 2024 to a low of -$133000.0 in Q3 2024.
• A 4-year average of $2.8 million and a median of $1.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 73.78% in 2024, while the deepest fall reached 107.82% in 2024.
• Tracing AKTX's Net Equity Issued and Repurchased over 4 years: stood at $5.4 million in 2021, then tumbled by 66.67% to $1.8 million in 2023, then soared by 73.78% to $3.1 million in 2024, then plunged by 84.67% to $479560.0 in 2025.
• Business Quant data shows AKTX's Net Equity Issued and Repurchased at $479560.0 in Q4 2025, $4.8 million in Q2 2025, and $1.1 million in Q1 2025.